Strategic Funding ARPA-H funding of up to $10 million signals strong validation of Probably Genetic’s AI platform and potential for expanded diagnostic capabilities. Leverage this momentum to position partnerships with life sciences firms and grant-funded collaborations that align with federal health initiatives.

Rare Disease Reach There is a vast underserved market of over 400 million people with rare diseases, with half undiagnosed and many children. Target collaborations with pharma and biotech firms seeking companion diagnostics, biomarker discovery, or targeted therapies to accelerate patient identification and trial recruitment.

Direct-to-Consumer Testing In-house genetic testing capability paired with symptom-based AI triage creates a streamlined funnel from symptom checker to testing to potential treatment access. Propose partnerships with patient advocacy groups and rare disease networks to expand patient access and test volume.

Sponsor Programs Current sponsored testing programs with drug developers indicate a clear path for white-label or co-branded testing initiatives. Present opportunities with pharmaceutical companies for sponsored testing, data insights, and faster enrollment in clinical programs.

Partnership Growth Past collaborations with APBDF, X4 Pharmaceuticals, and neurodegenerative focus suggest a receptive partner ecosystem. Prioritize outreach to rare disease foundations, biotech startups, and CROs seeking AI-driven diagnostic tools and scalable genetic testing services.